5-Methoxy-6-(oxan-2-yloxy)-2,3-dihydroinden-1-one | 1402062-93-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 5-Methoxy-6-(oxan-2-yloxy)-2,3-dihydroinden-1-one
• 英文别名: 5-methoxy-6-(oxan-2-yloxy)-2,3-dihydroinden-1-one
• CAS: 1402062-93-4
• 化学式: C₁₅H₁₈O₄
• 分子量: 262.306
• InChiKey: ODZOYDVODZTBEW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  异香兰素 、 5-Methoxy-6-(oxan-2-yloxy)-2,3-dihydroinden-1-one 在 盐酸 、 potassium hydroxide 作用下， 以 乙醇 、 水 、 乙酸乙酯 、 丁酮 为溶剂， 以62%的产率得到6-hydroxy-2-(3-hydroxy-4-methoxybenzylidene)-5-methoxy-2,3-dihydro-1H-inden-1-one
  参考文献：
  名称：

  Multitarget-Directed Benzylideneindanone Derivatives: Anti-β-Amyloid (Aβ) Aggregation, Antioxidant, Metal Chelation, and Monoamine Oxidase B (MAO-B) Inhibition Properties against Alzheimer’s Disease

  摘要：

  A novel series of benzylideneindanone derivatives were designed, synthesized, and evaluated as multitarget-directed ligands against Alzheimer's disease. The in vitro studies showed that most of the molecules exhibited a significant ability to inhibit self-induced beta-amyloid (A beta(1-42)) aggregation (10.5-80.1%, 20 mu M) and MAO-B activity (IC50 of 7.5-40.5 mu M), to act as potential antioxidants (ORAC-FL value of 2.75-9.37), and to function as metal chelators. In particular, compound 41 had the greatest ability to inhibit A beta(1-42) aggregation (80.1%), and MAO-B (IC50 = 7.5 mu M) was also an excellent antioxidant and metal chelator. Moreover, it is capable of inhibiting Cu(II)-induced A beta(1-42) aggregation and disassembling the well-structured A beta fibrils. These results indicated that compound 41 is an excellent multifunctional agent for the treatment of AD.

  DOI：

  10.1021/jm300978h
• 作为产物：
  描述：

  5,6-二甲氧基茚酮 在 4-甲基苯磺酸吡啶 、 三溴化硼 、 lithium carbonate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 13.0h， 生成 5-Methoxy-6-(oxan-2-yloxy)-2,3-dihydroinden-1-one
  参考文献：
  名称：

  Multitarget-Directed Benzylideneindanone Derivatives: Anti-β-Amyloid (Aβ) Aggregation, Antioxidant, Metal Chelation, and Monoamine Oxidase B (MAO-B) Inhibition Properties against Alzheimer’s Disease

  摘要：

  A novel series of benzylideneindanone derivatives were designed, synthesized, and evaluated as multitarget-directed ligands against Alzheimer's disease. The in vitro studies showed that most of the molecules exhibited a significant ability to inhibit self-induced beta-amyloid (A beta(1-42)) aggregation (10.5-80.1%, 20 mu M) and MAO-B activity (IC50 of 7.5-40.5 mu M), to act as potential antioxidants (ORAC-FL value of 2.75-9.37), and to function as metal chelators. In particular, compound 41 had the greatest ability to inhibit A beta(1-42) aggregation (80.1%), and MAO-B (IC50 = 7.5 mu M) was also an excellent antioxidant and metal chelator. Moreover, it is capable of inhibiting Cu(II)-induced A beta(1-42) aggregation and disassembling the well-structured A beta fibrils. These results indicated that compound 41 is an excellent multifunctional agent for the treatment of AD.

  DOI：

  10.1021/jm300978h

文献信息

• Multitarget-Directed Benzylideneindanone Derivatives: Anti-β-Amyloid (Aβ) Aggregation, Antioxidant, Metal Chelation, and Monoamine Oxidase B (MAO-B) Inhibition Properties against Alzheimer’s Disease
  作者：Ling Huang、Chuanjun Lu、Yang Sun、Fei Mao、Zonghua Luo、Tao Su、Huailei Jiang、Wenjun Shan、Xingshu Li

  DOI：10.1021/jm300978h

  日期：2012.10.11

  A novel series of benzylideneindanone derivatives were designed, synthesized, and evaluated as multitarget-directed ligands against Alzheimer's disease. The in vitro studies showed that most of the molecules exhibited a significant ability to inhibit self-induced beta-amyloid (A beta(1-42)) aggregation (10.5-80.1%, 20 mu M) and MAO-B activity (IC50 of 7.5-40.5 mu M), to act as potential antioxidants (ORAC-FL value of 2.75-9.37), and to function as metal chelators. In particular, compound 41 had the greatest ability to inhibit A beta(1-42) aggregation (80.1%), and MAO-B (IC50 = 7.5 mu M) was also an excellent antioxidant and metal chelator. Moreover, it is capable of inhibiting Cu(II)-induced A beta(1-42) aggregation and disassembling the well-structured A beta fibrils. These results indicated that compound 41 is an excellent multifunctional agent for the treatment of AD.